Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment.

Halaby MJ, Hezaveh K, Lamorte S, Ciudad MT, Kloetgen A, MacLeod BL, Guo M, Chakravarthy A, Medina TDS, Ugel S, Tsirigos A, Bronte V, Munn DH, Pugh TJ, De Carvalho DD, Butler MO, Ohashi PS, Brooks DG, McGaha TL.

Sci Immunol. 2019 Dec 13;4(42). pii: eaax8189. doi: 10.1126/sciimmunol.aax8189.

PMID:
31836669
2.

Methods to detect endogenous dsRNA induction and recognition.

Ettayebi I, Yau HL, De Carvalho DD.

Methods Enzymol. 2019;629:35-51. doi: 10.1016/bs.mie.2019.07.002. Epub 2019 Sep 3.

PMID:
31727248
3.

The role of DNA-demethylating agents in cancer therapy.

Mehdipour P, Murphy T, De Carvalho DD.

Pharmacol Ther. 2020 Jan;205:107416. doi: 10.1016/j.pharmthera.2019.107416. Epub 2019 Oct 15. Review.

PMID:
31626871
4.

Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.

Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, Ursini-Siegel J, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC.

Cancer Cell. 2019 Sep 16;36(3):338-339. doi: 10.1016/j.ccell.2019.08.012. No abstract available.

5.

Heart defibrillation: relationship between pacing threshold and defibrillation probability.

Antoneli PC, Goulart JT, Bonilha I, de Carvalho DD, de Oliveira PX.

Biomed Eng Online. 2019 Sep 13;18(1):96. doi: 10.1186/s12938-019-0715-5.

6.

Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA.

Shen SY, Burgener JM, Bratman SV, De Carvalho DD.

Nat Protoc. 2019 Oct;14(10):2749-2780. doi: 10.1038/s41596-019-0202-2. Epub 2019 Aug 30.

PMID:
31471598
7.

DNA Methylation as a Robust Classifier of Epithelial Ovarian Cancer.

Ishak CA, Lheureux S, De Carvalho DD.

Clin Cancer Res. 2019 Oct 1;25(19):5729-5731. doi: 10.1158/1078-0432.CCR-19-1797. Epub 2019 Jul 23.

PMID:
31337645
8.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

9.

The Mitochondrial Transacylase, Tafazzin, Regulates AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Aristizabal Henao JJ, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Jun 6;24(6):1007. doi: 10.1016/j.stem.2019.04.020. No abstract available.

PMID:
31173706
10.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

11.

Pervasive H3K27 Acetylation Leads to ERV Expression and a Therapeutic Vulnerability in H3K27M Gliomas.

Krug B, De Jay N, Harutyunyan AS, Deshmukh S, Marchione DM, Guilhamon P, Bertrand KC, Mikael LG, McConechy MK, Chen CCL, Khazaei S, Koncar RF, Agnihotri S, Faury D, Ellezam B, Weil AG, Ursini-Siegel J, De Carvalho DD, Dirks PB, Lewis PW, Salomoni P, Lupien M, Arrowsmith C, Lasko PF, Garcia BA, Kleinman CL, Jabado N, Mack SC.

Cancer Cell. 2019 May 13;35(5):782-797.e8. doi: 10.1016/j.ccell.2019.04.004. Erratum in: Cancer Cell. 2019 Sep 16;36(3):338-339.

PMID:
31085178
12.

The Mitochondrial Transacylase, Tafazzin, Regulates for AML Stemness by Modulating Intracellular Levels of Phospholipids.

Seneviratne AK, Xu M, Henao JJA, Fajardo VA, Hao Z, Voisin V, Xu GW, Hurren R, Kim S, MacLean N, Wang X, Gronda M, Jeyaraju D, Jitkova Y, Ketela T, Mullokandov M, Sharon D, Thomas G, Chouinard-Watkins R, Hawley JR, Schafer C, Yau HL, Khuchua Z, Aman A, Al-Awar R, Gross A, Claypool SM, Bazinet RP, Lupien M, Chan S, De Carvalho DD, Minden MD, Bader GD, Stark KD, LeBlanc P, Schimmer AD.

Cell Stem Cell. 2019 Apr 4;24(4):621-636.e16. doi: 10.1016/j.stem.2019.02.020. Epub 2019 Mar 28. Erratum in: Cell Stem Cell. 2019 Jun 6;24(6):1007.

PMID:
30930145
13.

Epigenetic therapy in immune-oncology.

Jones PA, Ohtani H, Chakravarthy A, De Carvalho DD.

Nat Rev Cancer. 2019 Mar;19(3):151-161. doi: 10.1038/s41568-019-0109-9. Review.

PMID:
30723290
14.

A chemical biology toolbox to study protein methyltransferases and epigenetic signaling.

Scheer S, Ackloo S, Medina TS, Schapira M, Li F, Ward JA, Lewis AM, Northrop JP, Richardson PL, Kaniskan HÜ, Shen Y, Liu J, Smil D, McLeod D, Zepeda-Velazquez CA, Luo M, Jin J, Barsyte-Lovejoy D, Huber KVM, De Carvalho DD, Vedadi M, Zaph C, Brown PJ, Arrowsmith CH.

Nat Commun. 2019 Jan 3;10(1):19. doi: 10.1038/s41467-018-07905-4.

15.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

16.

TGF-β-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure.

Chakravarthy A, Khan L, Bensler NP, Bose P, De Carvalho DD.

Nat Commun. 2018 Nov 8;9(1):4692. doi: 10.1038/s41467-018-06654-8.

17.

The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.

Loo Yau H, Ettayebi I, De Carvalho DD.

Trends Cell Biol. 2019 Jan;29(1):31-43. doi: 10.1016/j.tcb.2018.07.006. Epub 2018 Aug 25. Review.

PMID:
30153961
18.

Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer.

Ishak CA, Classon M, De Carvalho DD.

Trends Cancer. 2018 Aug;4(8):583-597. doi: 10.1016/j.trecan.2018.05.008. Epub 2018 Jun 19. Review.

PMID:
30064665
19.

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, Shi Y.

Cell. 2018 Jul 26;174(3):549-563.e19. doi: 10.1016/j.cell.2018.05.052. Epub 2018 Jun 21.

20.

Apoptotic cell-induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans.

Shinde R, Hezaveh K, Halaby MJ, Kloetgen A, Chakravarthy A, da Silva Medina T, Deol R, Manion KP, Baglaenko Y, Eldh M, Lamorte S, Wallace D, Chodisetti SB, Ravishankar B, Liu H, Chaudhary K, Munn DH, Tsirigos A, Madaio M, Gabrielsson S, Touma Z, Wither J, De Carvalho DD, McGaha TL.

Nat Immunol. 2018 Jun;19(6):571-582. doi: 10.1038/s41590-018-0107-1. Epub 2018 May 14.

21.

Soluble CD30, Acute Rejection, and Graft Survival: Pre- and 6-Month Post-Transplant Determinations-When Is the Best Time to Measure?

de Holanda MI, Matuck T, de Carvalho DDBM, Domingues EMFL, Curvo R, Glasberg DS, Santos AMG, Borela ÁM, Pôrto LC.

Transplant Proc. 2018 Apr;50(3):728-736. doi: 10.1016/j.transproceed.2018.02.025.

PMID:
29661425
22.

Cell-free DNA as a post-treatment surveillance strategy: current status.

Burgener JM, Rostami A, De Carvalho DD, Bratman SV.

Semin Oncol. 2017 Oct;44(5):330-346. doi: 10.1053/j.seminoncol.2018.01.009. Epub 2018 Feb 3. Review.

PMID:
29580435
23.

Drug-induced activation of "junk" DNA - A path to combat cancer therapy resistance?

Classon M, LaMarco K, De Carvalho DD.

Oncoscience. 2017 Oct 1;4(9-10):115-116. doi: 10.18632/oncoscience.364. eCollection 2017 Sep. No abstract available.

24.

BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.

Pereira WO, De Carvalho DD, Zenteno ME, Ribeiro BF, Jacysyn JF, Sardinha LR, Zanichelli MA, Hamerschlak N, Jones GE, Pagnano KB, Castro FA, Calle Y, Amarante-Mendes GP.

Cell Death Dis. 2017 Oct 12;8(10):e3114. doi: 10.1038/cddis.2017.458.

25.

O-Acetylation of Peptidoglycan Limits Helper T Cell Priming and Permits Staphylococcus aureus Reinfection.

Sanchez M, Kolar SL, Müller S, Reyes CN, Wolf AJ, Ogawa C, Singhania R, De Carvalho DD, Arditi M, Underhill DM, Martins GA, Liu GY.

Cell Host Microbe. 2017 Oct 11;22(4):543-551.e4. doi: 10.1016/j.chom.2017.08.008. Epub 2017 Sep 21.

26.

Epigenetic regulation of nitric oxide synthase 2, inducible (Nos2) by NLRC4 inflammasomes involves PARP1 cleavage.

Buzzo CL, Medina T, Branco LM, Lage SL, Ferreira LC, Amarante-Mendes GP, Hottiger MO, De Carvalho DD, Bortoluci KR.

Sci Rep. 2017 Feb 2;7:41686. doi: 10.1038/srep41686.

27.

Early-life antibiotic treatment enhances the pathogenicity of CD4+ T cells during intestinal inflammation.

Scheer S, Medina TS, Murison A, Taves MD, Antignano F, Chenery A, Soma KK, Perona-Wright G, Lupien M, Arrowsmith CH, De Carvalho DD, Zaph C.

J Leukoc Biol. 2017 Apr;101(4):893-900. doi: 10.1189/jlb.3MA0716-334RR. Epub 2016 Dec 29.

PMID:
28034915
28.

Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors.

Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DMA, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bognár L, Garami M, Hauser P, Hortobágyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Schüller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A.

Cancer Cell. 2016 Dec 12;30(6):891-908. doi: 10.1016/j.ccell.2016.11.003.

29.

Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Inoue S, Li WY, Tseng A, Beerman I, Elia AJ, Bendall SC, Lemonnier F, Kron KJ, Cescon DW, Hao Z, Lind EF, Takayama N, Planello AC, Shen SY, Shih AH, Larsen DM, Li Q, Snow BE, Wakeham A, Haight J, Gorrini C, Bassi C, Thu KL, Murakami K, Elford AR, Ueda T, Straley K, Yen KE, Melino G, Cimmino L, Aifantis I, Levine RL, De Carvalho DD, Lupien M, Rossi DJ, Nolan GP, Cairns RA, Mak TW.

Cancer Cell. 2016 Aug 8;30(2):337-348. doi: 10.1016/j.ccell.2016.05.018. Epub 2016 Jul 14.

30.

Pharmacological DNA demethylation: Implications for cancer immunotherapy.

Roulois D, Yau HL, De Carvalho DD.

Oncoimmunology. 2015 Nov 30;5(3):e1090077. eCollection 2016 Mar.

31.

Pre-neoplastic epigenetic disruption of transcriptional enhancers in chronic inflammation.

Planello AC, Singhania R, Kron KJ, Bailey SD, Roulois D, Lupien M, Line SR, de Souza AP, De Carvalho DD.

Oncotarget. 2016 Mar 29;7(13):15772-86. doi: 10.18632/oncotarget.7513.

32.

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

Roulois D, Loo Yau H, Singhania R, Wang Y, Danesh A, Shen SY, Han H, Liang G, Jones PA, Pugh TJ, O'Brien C, De Carvalho DD.

Cell. 2015 Aug 27;162(5):961-73. doi: 10.1016/j.cell.2015.07.056.

33.

IL17 Promotes Mammary Tumor Progression by Changing the Behavior of Tumor Cells and Eliciting Tumorigenic Neutrophils Recruitment.

Benevides L, da Fonseca DM, Donate PB, Tiezzi DG, De Carvalho DD, de Andrade JM, Martins GA, Silva JS.

Cancer Res. 2015 Sep 15;75(18):3788-99. doi: 10.1158/0008-5472.CAN-15-0054. Epub 2015 Jul 24.

34.

Diacerein improves left ventricular remodeling and cardiac function by reducing the inflammatory response after myocardial infarction.

Torina AG, Reichert K, Lima F, de Souza Vilarinho KA, de Oliveira PP, do Carmo HR, de Carvalho DD, Saad MJ, Sposito AC, Petrucci O.

PLoS One. 2015 Mar 27;10(3):e0121842. doi: 10.1371/journal.pone.0121842. eCollection 2015.

35.

Aberrant DNA methylation reprogramming during induced pluripotent stem cell generation is dependent on the choice of reprogramming factors.

Planello AC, Ji J, Sharma V, Singhania R, Mbabaali F, Müller F, Alfaro JA, Bock C, De Carvalho DD, Batada NN.

Cell Regen (Lond). 2014 Feb 7;3(1):4. doi: 10.1186/2045-9769-3-4. eCollection 2014.

36.

Gene body methylation can alter gene expression and is a therapeutic target in cancer.

Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, Liang G.

Cancer Cell. 2014 Oct 13;26(4):577-90. doi: 10.1016/j.ccr.2014.07.028. Epub 2014 Sep 25.

37.

High-throughput DNA analysis shows the importance of methylation in the control of immune inflammatory gene transcription in chronic periodontitis.

De Souza AP, Planello AC, Marques MR, De Carvalho DD, Line SR.

Clin Epigenetics. 2014 Aug 12;6(1):15. doi: 10.1186/1868-7083-6-15. eCollection 2014.

38.

Constitutive androstane receptor ligands modulate the anti-tumor efficacy of paclitaxel in non-small cell lung cancer cells.

Fukumasu H, Rochetti AL, Pires PR, Silva ER, Mesquita LG, Strefezzi RF, De Carvalho DD, Dagli ML.

PLoS One. 2014 Jun 24;9(6):e99484. doi: 10.1371/journal.pone.0099484. eCollection 2014.

39.

Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients.

Silva HT Jr, Felipe CR, Garcia VD, Neto ED, Filho MA, Contieri FL, de Carvalho DD, Pestana JO.

Am J Transplant. 2013 Dec;13(12):3155-63. doi: 10.1111/ajt.12481. Epub 2013 Oct 30.

40.

SNF5 is an essential executor of epigenetic regulation during differentiation.

You JS, De Carvalho DD, Dai C, Liu M, Pandiyan K, Zhou XJ, Liang G, Jones PA.

PLoS Genet. 2013 Apr;9(4):e1003459. doi: 10.1371/journal.pgen.1003459. Epub 2013 Apr 25.

41.

PRAME/EZH2-mediated regulation of TRAIL: a new target for cancer therapy.

De Carvalho DD, Mello BP, Pereira WO, Amarante-Mendes GP.

Curr Mol Med. 2013 Feb;13(2):296-304. Review.

PMID:
23228130
42.

DNA methylation screening identifies driver epigenetic events of cancer cell survival.

De Carvalho DD, Sharma S, You JS, Su SF, Taberlay PC, Kelly TK, Yang X, Liang G, Jones PA.

Cancer Cell. 2012 May 15;21(5):655-67. doi: 10.1016/j.ccr.2012.03.045.

43.

Polycomb-repressed genes have permissive enhancers that initiate reprogramming.

Taberlay PC, Kelly TK, Liu CC, You JS, De Carvalho DD, Miranda TB, Zhou XJ, Liang G, Jones PA.

Cell. 2011 Dec 9;147(6):1283-94. doi: 10.1016/j.cell.2011.10.040.

44.

OCT4 establishes and maintains nucleosome-depleted regions that provide additional layers of epigenetic regulation of its target genes.

You JS, Kelly TK, De Carvalho DD, Taberlay PC, Liang G, Jones PA.

Proc Natl Acad Sci U S A. 2011 Aug 30;108(35):14497-502. doi: 10.1073/pnas.1111309108. Epub 2011 Aug 15.

45.

Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure faithful epigenetic inheritance.

Sharma S, De Carvalho DD, Jeong S, Jones PA, Liang G.

PLoS Genet. 2011 Feb 3;7(2):e1001286. doi: 10.1371/journal.pgen.1001286.

46.

Epigenetic modifications as therapeutic targets.

Kelly TK, De Carvalho DD, Jones PA.

Nat Biotechnol. 2010 Oct;28(10):1069-78. doi: 10.1038/nbt.1678. Review.

47.

BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.

De Carvalho DD, Binato R, Pereira WO, Leroy JM, Colassanti MD, Proto-Siqueira R, Bueno-Da-Silva AE, Zago MA, Zanichelli MA, Abdelhay E, Castro FA, Jacysyn JF, Amarante-Mendes GP.

Oncogene. 2011 Jan 13;30(2):223-33. doi: 10.1038/onc.2010.409. Epub 2010 Sep 13.

PMID:
20838376
48.

DNA methylation and cellular reprogramming.

De Carvalho DD, You JS, Jones PA.

Trends Cell Biol. 2010 Oct;20(10):609-17. doi: 10.1016/j.tcb.2010.08.003. Epub 2010 Aug 31. Review.

49.

The cell wall fraction from Fonsecaea pedrosoi stimulates production of different profiles of cytokines and nitric oxide by murine peritoneal cells in vitro.

Nóbrega YK, Lozano VF, de Araújo TS, de Carvalho DD, Bocca AL.

Mycopathologia. 2010 Aug;170(2):89-98. doi: 10.1007/s11046-010-9303-8. Epub 2010 Mar 30.

PMID:
20352494
50.

Toxicity of phospholipases A2 D49 (6-1 and 6-2) and K49 (Bj-VII) from Bothrops jararacussu venom.

Bonfim VL, de Carvalho DD, Ponce-Soto LA, Kassab BH, Marangoni S.

Cell Biol Toxicol. 2009 Dec;25(6):523-32. doi: 10.1007/s10565-008-9106-6. Epub 2008 Oct 31.

PMID:
18975118

Supplemental Content

Loading ...
Support Center